[{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"a09b19fc-dabd-44da-a7d5-5bb06f2a03af","acronym":"NETs","url":"https://clinicaltrials.gov/study/NCT06821919","created_at":"2025-02-25T15:23:23.051Z","updated_at":"2025-02-25T15:23:23.051Z","phase":"","brief_title":"Impact of Antiglycemic \u0026 Immunosuppressive Therapies on NETosis in Diabetes \u0026 Kidney Disease (NETs - Neutrophil Traps)","source_id_and_acronym":"NCT06821919 - NETs","lead_sponsor":"Western Galilee Hospital-Nahariya","biomarkers":" MPO","pipe":"","alterations":" ","tags":["MPO"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/13/2024","start_date":" 05/13/2024","primary_txt":" Primary completion: 12/30/2030","primary_completion_date":" 12/30/2030","study_txt":" Completion: 12/30/2031","study_completion_date":" 12/30/2031","last_update_posted":"2025-02-12"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"639cf723-9b6c-4043-ad83-f6e28cb60edc","acronym":"MPO-MDS-Valid","url":"https://clinicaltrials.gov/study/NCT05175469","created_at":"2022-01-03T15:00:46.588Z","updated_at":"2024-07-02T16:35:15.042Z","phase":"","brief_title":"Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study","source_id_and_acronym":"NCT05175469 - MPO-MDS-Valid","lead_sponsor":"University Hospital, Grenoble","biomarkers":" MPO","pipe":"","alterations":" ","tags":["MPO"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-13"},{"id":"9315a3f2-ad9f-4b01-b650-234bd109bd92","acronym":"AALL08B1","url":"https://clinicaltrials.gov/study/NCT01142427","created_at":"2021-02-15T06:52:23.865Z","updated_at":"2024-07-02T16:35:34.957Z","phase":"","brief_title":"Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01142427 - AALL08B1","lead_sponsor":"Children's Oncology Group","biomarkers":" MPO","pipe":"","alterations":" ","tags":["MPO"],"overall_status":"Completed","enrollment":" Enrollment 17463","initiation":"Initiation: 08/09/2010","start_date":" 08/09/2010","primary_txt":" Primary completion: 05/01/2015","primary_completion_date":" 05/01/2015","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2023-10-03"},{"id":"7ab01d39-670d-4ac8-8661-c6da12d349fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06017141","created_at":"2023-08-30T14:08:47.576Z","updated_at":"2024-07-02T16:35:38.591Z","phase":"Phase 2","brief_title":"Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study","source_id_and_acronym":"NCT06017141","lead_sponsor":"University of Kansas Medical Center","biomarkers":" MPO","pipe":"","alterations":" ","tags":["MPO"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 05/22/2025","primary_completion_date":" 05/22/2025","study_txt":" Completion: 05/22/2026","study_completion_date":" 05/22/2026","last_update_posted":"2023-08-30"},{"id":"e3c309b4-3797-496b-ab13-ebb519b4a40f","acronym":"ABLE02","url":"https://clinicaltrials.gov/study/NCT04354233","created_at":"2021-01-18T21:03:39.421Z","updated_at":"2024-07-02T16:35:38.617Z","phase":"","brief_title":"A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer","source_id_and_acronym":"NCT04354233 - ABLE02","lead_sponsor":"Centre Leon Berard","biomarkers":" HER-2 • IFNG • IL6 • TNFA • IL10 • IL1B • CAT • MPO","pipe":"","alterations":" ","tags":["HER-2 • IFNG • IL6 • TNFA • IL10 • IL1B • CAT • MPO"],"overall_status":"Recruiting","enrollment":" Enrollment 244","initiation":"Initiation: 06/24/2020","start_date":" 06/24/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-30"},{"id":"928442ce-94f9-4c4c-b59a-ad55f16ee6b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04868747","created_at":"2021-05-03T12:04:24.405Z","updated_at":"2024-07-02T16:35:57.712Z","phase":"","brief_title":"The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping","source_id_and_acronym":"NCT04868747","lead_sponsor":"The Catholic University of Korea","biomarkers":" MPO","pipe":"","alterations":" ","tags":["MPO"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 04/02/2021","primary_completion_date":" 04/02/2021","study_txt":" Completion: 04/02/2021","study_completion_date":" 04/02/2021","last_update_posted":"2023-01-12"},{"id":"de16a910-2705-4a33-b85c-fdf50b60baf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05595109","created_at":"2022-10-26T13:56:26.429Z","updated_at":"2024-07-02T16:36:01.816Z","phase":"Phase 2/3","brief_title":"Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients","source_id_and_acronym":"NCT05595109","lead_sponsor":"Tanta University","biomarkers":" TNFA • MPO • NEFL","pipe":"","alterations":" ","tags":["TNFA • MPO • NEFL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 56","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 04/28/2023","primary_completion_date":" 04/28/2023","study_txt":" Completion: 10/28/2024","study_completion_date":" 10/28/2024","last_update_posted":"2022-10-26"},{"id":"f639df2f-b80b-4b0e-9bef-2bba3806e588","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496260","created_at":"2021-01-18T12:02:16.669Z","updated_at":"2024-07-02T16:36:16.063Z","phase":"","brief_title":"Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy","source_id_and_acronym":"NCT02496260","lead_sponsor":"Henry Ford Health System","biomarkers":" GDF15 • LGALS3 • CRP • MPO • NPPB","pipe":"","alterations":" ","tags":["GDF15 • LGALS3 • CRP • MPO • NPPB"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2022-03-03"},{"id":"d3150949-617e-4f1e-96a9-8e0ac2e34f54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05040347","created_at":"2021-09-10T16:57:21.656Z","updated_at":"2024-07-02T16:36:24.622Z","phase":"","brief_title":"Neutrophil Extracellular Traps as a Biomarker to Predict Portal Vein Tumor Thrombosis in Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05040347","lead_sponsor":"The Affiliated Hospital of Qingdao University","biomarkers":" MPO","pipe":"","alterations":" ","tags":["MPO"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 08/18/2020","start_date":" 08/18/2020","primary_txt":" Primary completion: 02/28/2021","primary_completion_date":" 02/28/2021","study_txt":" Completion: 02/28/2021","study_completion_date":" 02/28/2021","last_update_posted":"2021-09-10"},{"id":"712e9fbe-5df9-4835-8a1d-b353c3c1de22","acronym":"","url":"https://clinicaltrials.gov/study/NCT04732442","created_at":"2021-02-01T16:58:07.704Z","updated_at":"2024-07-02T16:36:35.333Z","phase":"","brief_title":"Changes in Inflammatory Response After Immunonutrition Compared to Standard Nutrition in Colorectal Cancer Tissue","source_id_and_acronym":"NCT04732442","lead_sponsor":"Jagiellonian University","biomarkers":" TNFA • CXCL8 • CXCL12 • CXCL2 • CXCL6 • CXCL1 • MPO","pipe":"","alterations":" ","tags":["TNFA • CXCL8 • CXCL12 • CXCL2 • CXCL6 • CXCL1 • MPO"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 11/30/2018","primary_completion_date":" 11/30/2018","study_txt":" Completion: 01/30/2019","study_completion_date":" 01/30/2019","last_update_posted":"2021-02-01"},{"id":"b2ce031b-5f74-4959-8185-34f9e490e6e5","acronym":"LAL0904","url":"https://clinicaltrials.gov/study/NCT00458848","created_at":"2021-02-15T06:52:15.281Z","updated_at":"2024-07-02T16:37:02.848Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00458848 - LAL0904","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" MPO","pipe":"","alterations":" ","tags":["MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • etoposide IV • vincristine • prednisone • daunorubicin • idarubicin hydrochloride • mitoxantrone • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 470","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2019-02-15"},{"id":"bc4c67cc-9e30-464e-af3b-77b5c83888ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01390337","created_at":"2021-01-18T05:42:19.412Z","updated_at":"2024-07-02T16:37:02.895Z","phase":"Phase 1","brief_title":"A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT01390337","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3 • MPO","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vanflyta (quizartinib) • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 02/01/2015","study_completion_date":" 02/01/2015","last_update_posted":"2019-02-12"},{"id":"f8bd6f77-81c1-447a-9e69-a90ff92fb536","acronym":"MPO-MDS-PILOT","url":"https://clinicaltrials.gov/study/NCT03363399","created_at":"2021-01-18T16:36:02.261Z","updated_at":"2024-07-02T16:37:06.626Z","phase":"","brief_title":"Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes","source_id_and_acronym":"NCT03363399 - MPO-MDS-PILOT","lead_sponsor":"University Hospital, Grenoble","biomarkers":" MPO","pipe":"","alterations":" ","tags":["MPO"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 02/22/2018","start_date":" 02/22/2018","primary_txt":" Primary completion: 09/06/2018","primary_completion_date":" 09/06/2018","study_txt":" Completion: 09/06/2018","study_completion_date":" 09/06/2018","last_update_posted":"2018-09-25"},{"id":"a0c28c79-4f79-4963-80d6-aeb7971347fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02270788","created_at":"2021-01-18T10:40:49.035Z","updated_at":"2024-07-02T16:37:17.373Z","phase":"Phase 1","brief_title":"Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies","source_id_and_acronym":"NCT02270788","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • MPO","pipe":"","alterations":" ","tags":["FLT3 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • crenolanib (ARO-002) • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/02/2015","start_date":" 04/02/2015","primary_txt":" Primary completion: 10/17/2016","primary_completion_date":" 10/17/2016","study_txt":" Completion: 10/17/2016","study_completion_date":" 10/17/2016","last_update_posted":"2017-10-03"}]